Global Genetic Disorders Partnering 2023: Trends, Financials and Players from Every Deal Since 2016

DUBLIN, April 4, 2023 /PRNewswire/ -- The "Global Genetic Disorders Partnering 2016-2023: Deal trends, players and financials" report has been added to  ResearchAndMarkets.com's offering.

Global Genetic Disorders Partnering 2016 to 2023 provides the full collection of genetic disorders disease deals signed between the world's pharmaceutical and biotechnology companies since 2016.

• Trends in genetic disorders partnering deals
• Financial deal terms for headline, upfront and royalty by stage of development
• Genetic disorders partnering agreement structure
• Genetic disorders partnering contract documents
• Top genetic disorders deals by value
• Most active genetic disorders dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive genetic disorders disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering genetic disorders deals.

The report presents financial deal terms values for genetic disorders deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of genetic disorders dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in genetic disorders dealmaking since 2016 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading genetic disorders deals since 2016. Deals are listed by headline value. The chapter includes the top 25 most active genetic disorders dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to genetic disorders deals since 2016 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all genetic disorders partnering deals by specific genetic disorders target announced since 2016. The chapter is organized by specific genetic disorders therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all genetic disorders partnering deals signed and announced since 2016. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in genetic disorders partnering and dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of genetic disorders technologies and products.

Report scope

Global Genetic Disorders Partnering 2016 to 2023 is intended to provide the reader with an in-depth understanding and access to genetic disorders trends and structure of deals entered into by leading companies worldwide.

Global Genetic Disorders Partnering 2016 to 2023 includes:

• Trends in genetic disorders dealmaking in the biopharma industry since 2016
• Access to headline, upfront, milestone and royalty data
• Access to hundreds of genetic disorders deal contract documents
• Comprehensive access to over 650 genetic disorders deal records
• The leading genetic disorders deals by value since 2016
• Most active genetic disorders dealmakers since 2016

The report includes deals for the following indications: Cystic Fibrosis (CF), Down syndrome, Fragile X Syndrome, Hereditary angioedema, Huntington's disease, Rare genetic disorders, Neurofibromatosis, Sickle cell disease, plus other genetic indications.

In Global Genetic Disorders Partnering 2016 to 2023, available deals and contracts are listed by:

• Headline value
• Upfront payment value
• Royalty rate value
• Stage of development at signing
• Deal component type
• Technology type
• Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Genetic Disorders Partnering 2016-2023 report provides comprehensive access to available deals and contract documents for over 650 genetic disorders deals.

Analyzing actual contract agreements allows assessment of the following:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are the sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Selection of Companies Mentioned

• 4D Molecular Therapeutics
• AAVLife
• Abbvie
• Abby Grace Foundation
• Abeona Therapeutics
• AdAlta
• Addex Therapeutics
• ADMA Biologics
• Aequus Pharmaceuticals
• Affectis Pharmaceuticals
• Affymetrix
• Agena Bioscience
• Agilis Biotherapeutics
• AGTC
• AiLife Diagnostics
• Akcea Therapeutics
• Alana Healthcare
• Alcyone Lifesciences
• Aldeyra Therapeutics
• Alexion Pharmaceuticals
• AllCells
• Allergan
• Alnylam Pharmaceuticals
• Altamira Pharma
• Altius Institute for Biomedical Sciences
• Ambry Genetics
• American Heart/Stroke Association
• American Society of Human Genetics
• AmerisourceBergen
• Amgros
• Amicus Therapeutics
• AMO Pharma
• AmorChem
• Angion Biomedica
• Annapurna Therapeutics
• Antabio
• Anthera Pharmaceuticals
• ANZAC Reserach Institute
• AOP Orphan Pharmaceuticals
• APG Bio
• Arbor Biotechnologies
• Arch Biopartners
• Arcturus Therapeutics
• Aridis Pharmaceuticals
• Ariosa Diagnostics
• ArmaGen
• ArQule
• Aruvant Sciences
• Asklepion Pharmaceuticals
• Astellas Pharma
• AstraZeneca
• Attain Health
• Auburn University
• Audentes Therapeutics
• Bambino Gesu Children's Hospital
• Bayer
• Baylor College of Medicine
• Baylor Genetics
• Berg
• Beyond Batten Disease Foundation
• BGI Americas
• Bicycle Therapeutics
• biOasis Technologies
• BioAxone Therapeutic
• BioBlast Pharma
• Biogen
• Biohealth Innovation
• Bioiatriki
• BioMarin Pharmaceutical
• Biomedical Catalyst Fund (UK)
• Biomnis
• BioPontis Alliance
• BioRealm
• BioSensics
• Bioverativ
• BioXcel
• Bloom Burton
• Bluebird Bio
• Blueprint Medicines
• Boehringer Ingelheim
• Brammer Bio
• BridgeBio Pharma
• Brigham and Women's Hospital
• Bristol-Myers Squibb
• Buck Institute for Age Research
• California Institute for Biomedical Research
• California Institute for Regenerative Medicine
• Calimmune
• Camurus
• CANbridge Life Sciences
• Cancer Prevention Pharmaceuticals
• Capnia
• CARB-X
• Cardinal Health
• Case Western Reserve University
• Casma Therapeutics
• Castle Creek Pharmaceuticals
• Celgene
• Center for Human Genetics and Laboratory Medicine
• Centers for Disease Control and Prevention
• Centogene
• Centre for Drug Research and Development (CDRD)
• CFTechnology.org
• Charcot-Marie-Tooth Association
• CHDI Foundation
• ChemDiv
• Children's Hospital Los Angeles
• Children's Hospital of Philadelphia
• Children's National Health System
• Children's Hospital Oakland Research Institute (CHORI)
• Chondrial Therapeutics
• Cincinnati Children's Hospital Medical Center
• Claire's Place Foundation
• Claritas Genomics
• Clementia Pharmaceuticals
• Clinic for Special Children
• Clinigen
• Columbia University Medical Center
• Concert Pharmaceuticals
• Confluence Pharmaceuticals
• Congenica
• Corbus Pharmaceuticals
• Courtagen Life Sciences
• CRISPR Therapeutics
• CTD Holdings
• Cure Duchenne
• Cure Sanfilippo Foundation
• CURx Pharmaceuticals
• Cyclacel Pharmaceuticals
• Cypher Genomics
• Cystic Fibrosis Foundation
• Cystic Fibrosis Foundation Therapeutics
• Cystic Fibrosis Trust
• Cystinosis Research Foundation
• Dainippon Sumitomo Pharma
• Daktari Diagnostics
• Dalton Pharma Services
• DarioHealth
• DaRui Biotech
• David and Barbara Roux
• DBV Technologies
• de Duve Institute
• DefiniGEN
• Department of Health and Human Services
• Department of Veterans Affairs
• Dermelix Biotherapeutics
• Dicerna Pharmaceuticals
• Dilaforette
• Dimension Therapeutics
• DMS Health Technologies
• Duchenne Therapy Network
• Duke University
• Dynacure
• Dystrophic Epidermolysis Bullosa Research Association of America
• Edico Genome
• Edimer Pharmaceuticals
• Eiger BioPharmaceuticals
• Elevian
• Elexopharm
• Eli Lilly
• Elixirgen
• Elucigene
• Emergent BioSolutions
• Emmaus Life Sciences
• Emmaus Medical
• Emory University
• EnBiotix
• Enterprise Therapeutics
• Enzyvant Science
• EpiDestiny
• Ergomed
• Erytech
• EspeRare Foundation
• Essentialis
• Esteve
• Eureka Genomics
• EUSA Pharma
• Evotec
• Ewopharma
• Exemplar Genetics
• Fabric Genomics
• Facio Therapies
• Ferring Pharmaceuticals
• Fertility SOURCE Companies
• Fibrocell Science
• Flemish agency for Innovation by Science and Technology
• Fluidigm
• Fondazione Telethon
• Food and Drug Administration (FDA)
• Fortress Biotech
• Foundation For Angelman Syndrome Therapeutics
• Foundation for the Children of the Californias
• Fox Chase Cancer Center
• FRAXA Research Foundation
• Friedreichs Ataxia Research Alliance
• FSHD Global Research Foundation
• Fudan University
• Fujitsu Laboratories
• Fulcrum Therapeutics
• Fulgent Genetics
• Galapagos
• Gamida Cell
• Geisinger Health System
• Genable Technologies
• Genea Biocells
• GeneDX
• GenePeeks
• Genethon
• Genetic Alliance
• Geneva University Hospitals
• Genoma
• Genome Institute of Singapore
• Genomic Vision
• Genzyme
• George Washington University
• Gilead Sciences
• GlaxoSmithKline
• Global Blood Therapeutics
• GNS Healthcare
• Good Start Genetics
• Grace Wilsey Foundation
• Great Ormond Street Hospital (GOSH)
• GtreeBNT
• Harvard University
• Helix
• Heptares Therapeutics
• Hereditary Neuropathy Foundation
• Hillhurst Biopharmaceuticals
• Horizon Discovery
• Icagen
• Icahn School of Medicine at Mount Sinai
• Illumina
• Immuneering
• ImmunoQure
• Imperial College London
• Imperial Innovations
• In-Depth Genomics
• Indiana University
• Indiana University-Purdue University Indianapolis
• Indian Institute of Science Education and Research
• InformedDNA
• Innovate UK
• Inova Translational Medicine Institute
• Inserm
• Inserm Transfert
• Insight Centre for Data Analytics
• Insilico
• Insmed Inc
• Institute for Genome Statistics and Bioinformatics
• Institute of Child Health
• Institute of Human Genetics
• Intel
• Intrexon
• Intrinsic LifeSciences
• Invitae
• Ionis Pharmaceuticals
• ISIS Innovation
• Israeli Ministry of Industry and Commerce
• IXICO
• Jackson Laboratory
• Janssen Pharmaceuticals
• Jazz Pharmaceuticals
• Jeffrey Modell Foundation
• Juvenescence
• K-PAX Pharmaceuticals
• Kadmon Pharmaceuticals
• Kamada
• Kings College London
• Komodo Health
• La Jolla Pharmaceutical
• Lannett
• Laurent Pharmaceuticals
• Lead Discovery Center
• Leadiant Biosciences
• Leidos
• Lenus Therapeutics
• Les Laboratoires Servier
• Levo Therapeutics
• LFB Biotechnologies
• Ligand Pharmaceuticals
• Linda Crnic Institute for Down Syndrome
• Louisiana State University
• Lumicera Health Services
• Luminex
• Lundbeck
• Lysogene
• Mallinckrodt Pharmaceuticals
• ManRos Therapeutics
• Marnier-Lapostolle Foundation
• Massachusetts Eye and Ear Infirmary
• Massachusetts General Hospital
• Massachusetts Institute of Technology
• Matinas Biopharma
• Mauli Ola Foundation
• Maxcyte
• Maxor National Pharmacy
• McGill University
• McKesson
• Medgenics
• Medical College of Wisconsin
• Medical University of South Carolina
• Medison Pharma
• MedPharm
• MeiraGTx
• Merck and Co
• Merck KGaA
• Mitsubishi Tanabe Pharma
• Moderna Therapeutics
• Molecular Stethoscope
• Morphic Therapeutic
• Mount Sinai Medical Center
• Murdoch Childrens Research Institute
• Mustang Bio
• Mylan Laboratories
• Nanopharmacia
• NantHealth
• Napa Therapeutics
• Natera
• National Center for Advancing Translational Sciences (NCATS)
• National Heart
• Lung and Blood Institute
• National Human Genome Research Institute
• National Institute of Allergy and Infectious Diseases
• National Institute of Child Health and Human Development
• National Institute of Mental Health
• National Institute of Neurological Disorders and Stroke
• National Institute on Aging
• National Institutes of Health
• National Newspaper Publishers Association
• National Organization for Rare Disorders
• National Psoriasis Foundation
• National Science Foundation
• National Taiwan University Hospital
• Nationwide Children's Hospital
• Navitas
• Necker Hospital
• Neurocrine Biosciences
• NeuroCycle Therapeutics
• NeuroPointDX
• Neurotrope BioScience
• NeuroVive Pharmaceutical
• New York Blood Center
• New Zealand Pharmaceuticals
• NextCODE Health
• NextGxDx
• NightstaRx
• Nippon Chemiphar
• Nippon Shinyaku
• Novartis
• Novation
• Novogen
• Novo Nordisk
• Novoteris
• Numedicus
• Onconova Therapeutics
• Oraxion Therapeutics
• Orchard Therapeutics
• ORIG3N
• Origin Biosciences
• Orsini Healthcare Specialty Pharmacy
• Ovid Therapeutics
• Oxford BioMedica

For more information about this report visit https://www.researchandmarkets.com/r/prpsk6

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470 
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716 

Logo:  https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg 

SOURCE Research and Markets